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Abstract
Background: Biannual mass drug administration (MDA) with praziquantel and additional interventions to eliminate
urogenital schistosomiasis has been implemented on the Zanzibar islands, United Republic of Tanzania, since
2012. We aimed to assess the coverage of school-based treatment (SBT) and community-wide treatment
(CWT), to validate the coverage reported by the Zanzibar Ministry of Health (MoH) and to identify reasons
for non-compliance.
Methods: We conducted a post-MDA cross-sectional survey in 93 schools and 92 communities on Pemba and Unguja
islands in early 2014, 3–5 months after the last MDA round. Pupils and adults were asked whether they had received
and taken the praziquantel treatment provided in the last SBT or CWT, respectively, and the observed and reported
coverage were compared. Reasons for non-compliance were recorded in a pretested questionnaire and assessed in
qualitative interviews. Urine samples of participants were examined for Schistosoma haematobium eggs with a single
urine filtration.
Results: Around 8000 pupils and 4000 adults were included in the analysis. Our survey revealed a SBT coverage of
85.2 % in Pemba and of 86.9 % in Unguja, which was in line with MoH reports from Pemba (84.3 %) and higher than
reports from Unguja (63.9 %). However, 15 among the 48 schools surveyed in Unguja had not received SBT. Among
the interviewed adults, 53.6 % in Pemba and 64.9 % in Unguja had received praziquantel during CWT, which was
less than the 59.0 % and 67.7 %, respectively, indicated by MoH reports. Moreover, only 43.8 % and 54.0 % of adults
in Pemba and Unguja, respectively, had taken all the tablets as recommended. The main reasons for not receiving
or taking praziquantel were absence during CWT, no drug distributor coming, being busy, fear of adverse events,
pregnancy, breastfeeding or feeling healthy.
Conclusion: To increase coverage and compliance in Zanzibar, SBT should target all schools and mobilization,
sensitization and implementation of the CWT need to be improved. To reach elimination of urogenital schistosomiasis
transmission in Zanzibar and elsewhere, a very high treatment coverage and compliance at national and local level is
key and additional control measures such as snail control and behaviour change interventions will need to be
implemented area wide.
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Background
For almost a century, urogenital schistosomiasis has
been recognised as a public health problem on the
Zanzibar islands that form part of the United Republic
of Tanzania [1–3]. The first programme to control mor-
bidity of the disease dates back to 1986 on Pemba island
[4]. Since then, considerable progress in the control of
urogenital schistosomiasis and other neglected tropical
diseases (NTDs), such as soil-transmitted helminthiasis
and lymphatic filariasis, has been made [5–8]. Between
1994 and 1999, children and sometimes entire commu-
nities were treated annually with praziquantel for schis-
tosomiasis and with albendazole for soil-transmitted
helminthiasis [9]. In 2001, mass drug administration
(MDA) against lymphatic filariasis was started and iver-
mectin and albendazole were distributed to all at-risk
communities in Unguja and Pemba in six treatment
rounds, the latest being implemented in 2006 [5, 9, 10].
Additionally, between 2003 and 2007, several hundred
thousand schoolchildren were treated annually with
praziquantel for schistosomiasis and with albendazole
for soil-transmitted helminthiasis in the framework of
the Piga vita Kichocho Programme and supported by the
Schistosomiasis Control Initiative (SCI) on Unguja and
Pemba islands [6]. After a period of intermittent treatment
efforts between 2008 and 2011, biannual community-wide
treatment (CWT) with praziquantel and albendazole were
instituted in 2012 with the start of the Zanzibar Elimination
of Schistosomiasis Transmission (ZEST) project, which
aims to eliminate urogenital schistosomiasis transmission
from Unguja island and to eliminate urogenital schis-
tosomiasis as a public health problem from Pemba
island [11, 12].
In the frame of ZEST, a multi-year randomised oper-
ational research project, funded by the Schistosomiasis
Consortium for Operational Research and Evaluation
(SCORE), was implemented to assess whether snail
control and behaviour change interventions as
complementary measures to MDA have a larger impact
on S. haematobium prevalences and infection intensities
than MDA alone [11, 12]. Since April 2012, CWT with
praziquantel and albendazole is implemented twice a
year by the NTD Control Programme of the Zanzibar
Ministry of Health. School-based treatment (SBT) was
introduced as an additional venue for MDA in November
2013, with an aim to further improve the coverage of
school-aged children.
Achieving and maintaining high MDA coverage is
essential for the success of helminth control and
elimination programmes [13–15]. In countries aiming to
control morbidity due to schistosomiasis and soil-
transmitted helminthiasis, the World Health Organization
(WHO) has set the target to reach 100 % geographical and
at least 75 % national coverage [15, 16]. To achieve
interruption of transmission and elimination of schisto-
somiasis, it is recommended to increase the frequency of
treatment and to consolidate MDA by additional control
measures such as snail control, behaviour change inter-
ventions and improved access to water and sanitation [15,
17, 18]. Coverage is also considered a minimum process
indicator for assessing the performance of large-scale pre-
ventive chemotherapy interventions [13, 15]. To monitor
the progress of helminthiasis control programmes and the
success of MDA, programme managers are supposed to
compile data recorded in registers by community drug
distributors (CDDs) during MDA and to calculate the
programme coverage based on the number of people
treated divided by the number of persons at risk for the
target disease [19]. National authorities are expected to
submit their programme report, including the coverage
achieved in their helminth control programmes to WHO
on an annual basis [20]. In theory, programme coverage
refers to the proportion of individuals in the target popu-
lation who have actually swallowed the recommended
drug or drug combinations in the designated endemic area
[20]. In practice, coverage data are often calculated based
on the number of tablets distributed to the target popula-
tion [19]. Since the intake of the drugs cannot always be
directly observed by CDDs, it is recommended to conduct
random cluster surveys to assess the actual coverage in-
cluding drug intake, here termed compliance [13, 21].
To validate the accuracy of country reported MDA
coverage rates, it is recommended to conduct periodic-
ally post-MDA surveys implemented by trained inter-
viewer teams that were not involved in the MDA
implementation [14, 19].
We aimed to assess the SBT and CWT coverage with a
post-MDA survey conducted within the annual parasito-
logical survey of the SCORE study, 3–5 months after the
SBT and CWT had been implemented on Pemba and
Unguja islands in November 2013. Moreover, we wished
to elucidate reasons for not receiving or taking prazi-
quantel and, finally, we aimed to validate the accuracy of
the coverage rates reported by the MoH according to
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data collected by local CDDs and to draw recommenda-
tions for improving future treatment coverage and schis-
tosomiasis control and elimination efforts in Zanzibar
and elsewhere. To substantiate our quantitative findings,
we occasionally added quotes from a small qualitative
inquiry that had been conducted with community mem-
bers in August 2013 to identify potential barriers to
taking praziquantel (unpublished report; Person, B.
“A human centered design project. The Zanzibar
elimination of schistosomiasis transmission study: year 2
qualitative research findings on the behavioral interven-
tion”; December 2013).
Methods
Ethics statement
Ethical approval for the protocol of the randomised
intervention trial “Study and implementation of schisto-
somiasis elimination in Zanzibar (Unguja and Pemba
Islands) using an integrated multidisciplinary approach”
funded by SCORE was obtained from the Zanzibar Med-
ical Research Ethics Committee (ZAMREC; reference
no. ZAMREC 0003/Sept/011), the “Ethikkommission
beider Basel” (EKBB) in Switzerland (reference no. 236/
11) and the Institutional Review Board of the University
of Georgia (project no. 2012-10138-0). The study is reg-
istered at the International Standard Randomised Con-
trolled Trial Number Register (ISRCTN48837681).
Before the onset of the annual parasitological survey
including questionnaire interviews in March 2014, the
district health and school authorities were informed
about the aims and objectives of the study and about the
survey dates. On the day of the survey, the headmaster
of the school and the community leader (sheha) were
visited by a senior member of the field team, who ex-
plained the purpose and procedures of the study verbally
and asked for permission to carry out the survey in the
school or community. The study was also explained in
lay terms to the schoolchildren and adult participants,
who additionally received an information sheet and a
consent form to sign. Minors (e.g. children below the
age of 16 years) were asked for written informed consent
by their parent/guardian. All participants were offered
praziquantel (40 mg/kg) for schistosomiasis and alben-
dazole (400 mg) for soil-transmitted helminthiasis free
of charge as part of the island-wide MDA round con-
ducted in August 2014.
Study area and population
Tanganyika and the Zanzibar islands established the
United Republic of Tanzania in April 1964. The two
main islands of the Zanzibar archipelago, Unguja and
Pemba, are located approximately 30 km and 50 km, re-
spectively, east of mainland Tanzania in the Indian
Ocean. Both islands are divided into districts, which are
further split into a total of 331 small administrative areas
(shehias) [22]. According to the 2012 population and
housing census, Pemba has 121 and Unguja 210 regis-
tered shehias, an approximate combined population of
1.3 million inhabitants and an average household size of
5.1 people [22, 23]. In 2012, there were 194 primary
schools in Zanzibar. The net enrolment rate in primary
schools was 83.7 %, with a net proportion of that popu-
lation of 79.1 % and 4.6 % in public and private primary
schools, respectively [24]. Urogenital schistosomiasis
caused by S. haematobium was highly prevalent in Unguja
and Pemba in the 1980s [4, 25, 26]. It is the only autoch-
thonous form of schistosomiasis on the islands, since the
only intermediate host snail species present is Bulinus
globosus [27]. Social improvements and repeated MDA with
praziquantel over the past decades have reduced prevalence
and morbidity to low levels, and hence elimination of
urogenital schistosomiasis seems feasible [8, 11, 28].
Implementation of SBT and CWT in Zanzibar in
November 2013
Biannual CWT has been implemented by the Zanzibar
MoH as part of the strategy to eliminate urogenital
schistosomiasis since April 2012 and followed the “3-
year comprehensive strategic plan to combat neglected
tropical diseases in Zanzibar 2009/2011”, referred to as
the National Plan [11, 29]. The CWT conducted in No-
vember 2013 was the fourth treatment round. With the
aim to achieve a higher coverage and compliance of the
school-aged population, SBT was added as an additional
venue in MDA and implemented for the first time in the
framework of the ZEST project in November 2013. The
SBT followed a directly observed treatment (DOT) ap-
proach and was conducted over several weeks by mem-
bers of the NTD Control Programme of the Zanzibar
MoH in close collaboration with teachers and shehas.
All public primary schools in Pemba and all public pri-
mary schools in the North A, North B, Central, West
and Urban C districts in Unguja were supposed to be
targeted with albendazole and praziquantel. All schools
were advised to provide porridge to the children on the
day of SBT to reduce the frequency of potential drug-
related adverse events [30–32]. The CWT was imple-
mented across Pemba and Unguja islands on 29th and
30th November, 2013, by trained CDDs, supervised by
members of the NTD Control Programme of the Zanzibar
MoH and District Health Management Teams. The CDDs
used a door-to-door approach to distribute albendazole
and praziquantel to all people in Zanzibar, with the excep-
tion of children below the age of 3 years, children who
had received treatment in the SBT, pregnant women and
severely sick persons. Praziquantel was supposed to be
distributed using a dose pole [33, 34]. Noteworthy, the ex-
clusion of pregnant women from praziquantel treatment
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was based on local guidelines. The WHO recommends
the treatment of pregnant and lactating women [13, 35]
and efforts are currently underway in Zanzibar to adapt
the local guidelines accordingly.
Study design
The post-MDA survey described here was embedded in
the annual parasitological survey of the SCORE rando-
mised operational research project, carried out from
March to May 2014, 3–5 months after the SBT and
CWT were conducted in Zanzibar in November 2013.
In line with the SCORE study protocol, where the study
design and sample size calculations are described in de-
tail [11], a total of 45 schools and 45 shehias were in-
cluded in the cross-sectional survey on Pemba island
and a total of 48 schools and 47 shehias were surveyed
on Unguja island. In each school, approximately 130
children from standards 3 and 4 were randomly selected
to participate. In each shehia, 50 adults were randomly
selected to participate. For analysis, the shehias and
schools on each island served as primary sampling units.
Field procedures
Before the onset of the study, all shehas and headmas-
ters of the schools were informed about the purpose of
the project and asked for their support during the study.
According to the protocol [11], all children aged 9–12
years visiting the study schools were eligible to partici-
pate. This age group is primarily found in standards 3
and 4, and hence, in each primary school visited, the
study was explained to children from these grades, be-
fore 130 children were randomly selected and invited to
participate. For randomization, all eligible children lined
up, in separate lines for boys and girls and grade. Subse-
quently, each third child in the lines was systematically
selected to be included in the study. This procedure was
continued until we reached a total of 130 selected chil-
dren, accounting for a 20 % drop-out with the final aim
to sample 100 children aged 9–12 years. The selected
children were registered and their age, sex and participa-
tion at the last SBT were recorded. Subsequently, they
received an information sheet and a consent form, which
they were asked to return the following day with a signa-
ture of their parent/guardian. On the next day, children
that provided a signed consent form were given a
labelled transparent container (100 ml) with lid and
invited to submit an own urine sample between 10:00
and 12:00 h.
In the shehias, we selected a quota sample of 50
houses per shehia according to a method suggested by
Winkler et al. [36]. For randomisation, a gyro with a
marked arrow-star (equal to the number of field inter-
viewers in a team) pointing into different directions was
spun on a central point in the shehia [11]. Subsequently,
each interviewer counted the households to the edge of
the shehia following a path in the direction of the arrow.
On return to the centre point, the number of house-
holds in that direction was reported and the interviewer
stated a number within the range of the counted
households. The number was compared to a list with
computer-generated random numbers created for each
shehia. The random number corresponding to the num-
ber stated by the interviewer assigned where to start the
first questionnaire interview. Subsequently, the neigh-
bouring households were visited. In total, 50 individuals
from 50 households were invited to participate. A house-
hold was defined as “a group of persons who normally
live and eat together”. In case there was more than one
household member present at the time when the field-
worker knocked at the door, a member was randomly se-
lected by drawing cards. However, since generally more
women than men were present at home at the time of
the household visits, each fieldworker was advised that
at least a third of the participants should be male. The
age range for participation was 20–55 years, according
to the SCORE study protocol [11]. After signing a con-
sent form to participate, each individual was interviewed
with a closed-ended questionnaire about the participa-
tion at the last CWT in November 2013, i.e. whether he/
she knew, which disease was treated with praziquantel (a
picture of different drugs distributed during the CWT,
including praziquantel, was shown), whether he/she had
received praziquantel, had been measured for height,
had taken praziquantel, and had taken all praziquantel
tablets together or split the intake. When people had not
received or taken the tablets, the reason was recorded.
Finally, the interviewee was invited to submit a urine
sample for examination for a S. haematobium infection
between 10:00 and 14:00 h.
Laboratory procedures
All urine samples were brought back to the Helminth
Control Laboratory on Unguja and the Public Health
Laboratory—Ivo de Carneri on Pemba on the day of
collection. Urine samples were inspected for micro-
haematuria using reagent strips (Hemastix; Siemens
Healthcare Diagnostics GmbH, Eschborn, Germany) and
for S. haematobium eggs by filtering 10 ml of urine through
a polycarbonate filter (Sterlitech, Kent, United States of
America) and subsequent quality controlled microscopy of
the filter by experienced laboratory technicians.
Data management and analysis
Registration details of pupils and laboratory results of
children and adults participating in the SCORE annual
parasitologal survey were entered into a Microsoft Excel
spreadsheet (version 10.0; 2002 Microsoft Corporation).
Questionnaire data of adults were entered into EpiInfo
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version 3.5.1 (Centers for Disease Control and Prevention,
Atlanta, United States of America). Statistical analyses were
carried out with STATA version 12 (StataCorp., College
Station, United States of America). A Microsoft Excel data-
base, including the numbers of children treated and regis-
tered in the schools as recorded by the NTD Control
Programme team members and teachers who conducted
the SBT and the number of people treated and recorded by
the CDDs conducting CWT, stratified by school, shehia,
district and island, was provided by the MoH.
Only children aged 9–12 years and adults aged 20–55
years, who provided a written informed consent, responded
to the questions about their participation at the SBT or
CWT and had a complete urine analysis (i.e. reagent strip
assessment plus urine filtration) were included into the final
analysis of our SCORE post-MDA survey.
An individual was considered microhaematuria-positive,
when the reagent strip colour was coded trace, +, ++
or +++, according to the manufacturer’s instructions.
An individual was considered as schistosomiasis-positive,
when at least one S. haematobium egg was identified on
the urine filter.
Coverage was calculated as follows: first, in our
SCORE post-MDA survey in the schools and communi-
ties, we estimated the proportion of pupils and adults,
respectively, who received praziquantel among those
who were interviewed and included into our analysis.
Second, we calculated the proportion of adults who had
received and taken praziquantel among those who were
interviewed and included into our analysis. Third, we ex-
cluded adults that might have been considered as not
eligible for treatment by the MoH (pregnant, breastfeed-
ing or ill) from the analysis and calculated the propor-
tion of individuals who had received praziquantel.
Fourth, we again excluded potentially not eligible (preg-
nant, breastfeeding or ill) adults from the analysis and
calculated the proportion of individuals who had re-
ceived and taken praziquantel. Fifth, with regard to the
data obtained from the MoH, we calculated coverage as
the proportion of treated individuals among the total
population as recorded by the CDDs. Sixth, we calcu-
lated coverage as the proportion of treated individuals
among the population considered as eligible by the
MoH. Country-reported coverage data were considered
accurate if they fell within the 95 % confidence intervals
(CI) of the survey coverage rates [19]. Prevalences and
coverage rates, including 95 % CIs, were calculated
taking into account the cluster survey design and using
svyset and svy: commands in Stata. Design effects were
estimated for the survey coverage rates. Risk factors for
S. haematobium infection as outcome (binary) were
assessed with multivariable regression analysis, using
treatment (binary), sex (binary) and age (continuous in
years) as explanatory.
Results
Study participation
As shown in Fig. 1, a total of 5684 and 5327 pupils in
Pemba and Unguja, respectively, were invited and regis-
tered to participate in our parasitological survey. In
Pemba, a total of 5036 children from all 45 SCORE
schools had complete data and were included in the ana-
lysis. Among them, 2683 were girls and 2353 were boys.
In Unguja, complete data were available from 4739 pu-
pils. However, among them, 1444 children attended one
of 15 schools that were not targeted by the SBT and
were excluded from further analysis. Ultimately, in
Unguja, a total of 3295 children were included in the
final analysis. Among them, 1740 were girls and 1555
were boys.
Figure 2 shows that a total of 2250 and 2351 adults in
Pemba and Unguja, respectively, consented to partici-
pate in our study. Inclusion criteria were fulfilled by
2231 adults in Pemba and by 2323 adults in Unguja.
Among them, 60.4 % in Pemba and 65.9 % in Unguja
were female.
Praziquantel treatment coverage in SBT and CWT
according to the SCORE post-MDA survey
In Pemba, SBT had been carried out in all 45 SCORE
schools. As shown in Table 1, 85.8 % of interviewed pu-
pils reported that they had taken praziquantel during the
SBT. The remaining children stated that they were not
present at the SBT and had not received praziquantel
during the CWT. The coverage was higher in girls
(88.8 %) than in boys (82.4 %). In Unguja, only children
from 33 among the 48 schools included in the annual
SCORE survey reported that they had participated at the
SBT. Among the children that attended one of the 33
covered schools, 83.1 % reported that they had ingested
praziquantel during the SBT. The coverage was similar
among girls (83.9 %) and boys (82.1 %).
In Pemba, among the 2231 interviewed adult partic-
ipants, 53.6 % confirmed that they had received prazi-
quantel in the CWT. However, only 43.8 % had
swallowed all received tablets together. Considering
that only 602 adults who had received and taken all
praziquantel tablets together had also been measured
for height, a proper intake of drugs can be assumed
for 27.0 % of adults.
In Unguja, among the 2323 adults included in the ana-
lysis, 65.4 % reported that they had received praziquantel
from a CDD and 54.2 % had taken the drugs. However,
height had only been measured for 913 individuals.
Hence, a proper praziquantel intake can be assumed for
39.3 % of adults.
Noteworthy, among adults interviewed in Pemba and
Unguja, only 69.3 % and 36.5 %, respectively, recognised
praziquantel as the drug to treat schistosomiasis. In
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Pemba, 29.8 % and in Unguja 49.6 % of adults stated
they did not know which disease was treated with the re-
ceived tablets. Intestinal worms, lymphatic filariasis,
malaria and eye disease were incorrectly mentioned as
diseases that could be treated with praziquantel.
Reasons for not receiving or taking praziquantel in
the CWT
In Pemba, 1254 adults did not receive or did not take all
praziquantel tablets together. Among them, 92.2 % pro-
vided at least one reason for not having received or
taken the drug (Table 2). Reasons including the local
treatment guideline exclusion criteria applied by the
MoH were pregnancy (16.7 %), breastfeeding (5.8 %) and
illness (2.6 %). Other main factors were absenteeism
(39.3 %), being busy (7.6 %), no CDD coming to the
house (6.6 %), being afraid of adverse events (6.4 %) or
considering themselves as healthy (6.1 %).
In Unguja, only 65.9 % among the 1066 adults who
had not received or taken all praziquantel tablets to-
gether provided at least one reason for the non-
compliance: pregnancy, breastfeeding and being ill were
mentioned by 23.3 %, 5.2 % and 3.9 %; absenteeism on
the days of CWT was reported from 41.9 % and no
CDD visiting the house was stated by 14.9 % of adults.
In our earlier qualitative inquiry, people described dif-
ficulties in taking the large number of tablets provided
during the CWT. A 51-year-old health worker from
Pemba said, “I suggest that you should divide the tablets
into two parts because some people are weak they cannot
afford to take a lot of drugs at the same time. It would
also avoid complications or drug reactions”. (Int. 11). A
44 year-old teacher from Unguja told us, “You know, for
our people it is difficult to swallow many tablets at the
same time because of their health. If we are given nearly
ten tablets—tablets for the helminths, filariasis and these
Fig. 1 Participation of 9- to 12-year-old pupils in the post-mass drug administration survey conducted in Zanzibar
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kichocho [schistosomiasis] tablets, it would not be good. I
think the government should reduce the number of the
tablets as we know our people. They will take the tablets
but not swallow them”. (Int. 50).
Adults and children also expressed concerns over
drug-related adverse events. A woman’s group leader re-
ported, “I knew they [children] had received the drugs be-
cause they came home and told me. They came home
complaining about abdominal discomfort after being
given the drugs at school. They are given the drugs after
every six or so months…am not sure….but I know they
are given the drugs at school”. (Int. 65) Another person
reported, “These tablets are powerful so some people get
dizziness when they swallow them. So they are afraid.
Some of them they get vomiting too”. (Int. 97)
Coverage reported by MoH versus results from the
SCORE post-MDA survey
The maps in Fig. 3 show the observed and reported
coverage rates achieved with SBT and CWT in Pemba
and Unguja, stratified into high (≥75.0 %), moderate
(50.0–74.9 %) and low (<50.0 %) coverage. In regard
to SBT, in Pemba, 43 among the 45 SCORE schools
were included in the MoH database and could be
compared to our SCORE post-MDA survey. In these
schools, the MoH reported a SBT coverage of 84.3 %
and our survey revealed a coverage of 85.2 % (95 %
CI: 81.8–88.6 %) (Table 3).
In Unguja, only 27 among the 48 SCORE schools had
treatment reports from both, MoH and our SCORE post-
MDA survey. Among the 21 “missing” schools, 13 had
reported that they were not targeted by the SBT in our
post-MDA survey and were also not listed in the MoH
database; six schools had indicated SBT in our post-MDA
survey but were not listed in the MoH database; and two
schools were listed in the MoH database but no child
from standards 3 and 4 had indicated treatment in our
survey. In the 27 “available” schools, the coverage was
63.9 % according to MoH data and 86.9 % (95 % CI: 81.0–
92.9 %) according to the SCORE post-MDA survey.
In regard to the CWT, in Pemba, all 45 SCORE shehias
were listed in the MoH database. Considering the total
population recorded by the CDDs as denominator, the
MoH data resulted in a coverage of 59.0 %, while the
SCORE post-MDA survey showed that 53.6 % (95 % CI:
50.4–56.8 %) of the participants had received praziquantel,
Fig. 2 Participation of 20- to 55-year-old adults in the post-mass drug administration survey conducted in Zanzibar
Knopp et al. Parasites & Vectors  (2016) 9:5 Page 7 of 14
but that only 43.8 % (95 % CI: 40.5–47.1 %) had taken all
drugs together. If the population recorded by the CDD as
eligible was taken as denominator, the MoH reported
coverage was 82.0 %. If pregnant, lactating and ill people
were excluded from the SCORE post-MDA survey ana-
lysis, 60.1 % (95 % CI: 56.5–63.7 %) of adults had received
praziquantel, but only 50.3 % (95 % CI: 46.6–54.0 %) had
taken all tablets together.
In Unguja, among the 47 shehias surveyed for the
SCORE post-MDA survey, 43 had valid entries in the
MoH database. The praziquantel coverage in the total
population was 67.7 % according to the CDD reports
Table 1 Coverage and compliance in school-based and community-wide treatment carried out in Zanzibar in November 2013
Unguja Pemba
n % n %
School survey
Schools 33 (of 48) 45 (of 45)
Pupils 3295 5036
Boys 1555 2353
Girls 1740 2683
Did not receive or swallow praziquantel 558 16.9 715 14.2
Boys 278 415
Girls 280 300
Received and swallowed praziquantel 2737 83.1 4321 85.8
Boys 1277 82.1 1938 82.4
Girls 1460 83.9 2383 88.8
Adult survey
Shehias 47 (of 47) 45 (of 45)
Adults 2323 2231
Men 793 884
Women 1530 1347
Did not receive praziquantel (or did not know if received) 804 34.6 1035 46.4
Men 263 33.2 422 47.7
Women 541 35.4 613 45.5
Received praziquantel 1519 65.4 1196 53.6
Men 530 66.8 462 52.3
Women 989 64.6 734 54.5
If received praziquantel: Took all praziquantel together 1263 83.1 977 81.7
Men 433 81.7 391 84.6
Women 830 83.9 586 79.8
If received praziquantel: Did not take praziquantel or did not know 256 16.9 219 18.3
Men 97 18.3 71 15.4
Women 159 16.1 148 20.2
Did not receive or did not take praziquantel 1060 45.6 1254 56.2
Men 360 45.4 493 55.8
Women 700 45.8 761 56.5
Received and took all praziquantel together 1263 54.4 977 43.8
Men 433 54.6 391 44.2
Women 830 54.2 586 43.5
Received and took all praziquantel together and were measured for height 913 39.3 602 27.0
Men 298 37.6 221 25.0
Women 615 40.2 381 28.3
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and 64.9 % (95 % CI: 60.7–69.1 %) in our survey. How-
ever, only 54.0 % (95 % CI: 50.3–57.7 %) of our study
population had taken all praziquantel tablets together.
Considering only the eligible population, the reported
and observed coverage was 80.6 % and 71.2 % (95 % CI:
66.6–75.8 %), respectively and 60.1 % (95 % CI: 55.9–
64.4 %) had finally taken all tablets together.
Prevalence of S. haematobium in the study population
In Pemba, the overall prevalence of microhaematuria and
S. haematobium infection in the 45 schools was 7.4 % (95 %
CI: 5.4–9.5 %) and 5.4 % (95 % CI: 3.4–7.3 %), respectively.
Treated children had significantly lower odds than untreated
children (OR: 0.5; 95 % CI: 0.3–0.9 %) and boys had
significantly higher odds than girls (OR: 1.8; 95 % CI: 1.3–
2.6 %) of being infected with S. haematobium.
In Unguja, the overall prevalence of microhaematuria
and S. haematobium infection in the 33 treated schools
was 7.4 % (95 % CI: 4.6–10.3 %) and 5.2 % (95 % CI:
1.9–8.5 %), respectively. In the 15 schools that were not
covered by SBT, the overall prevalence of microhaematuria
was 3.7 % (95 % CI: 2.5–4.9 %) and of S. haematobium
infection was 2.2 % (95 % CI: 0.8–3.6 %). Boys had signifi-
cantly higher odds of harbouring a S. haematobium infec-
tion than girls (OR: 1.7; 95 % CI: 1.1–2.7 %).
In the adults residing in one of the 45 SCORE shehias
in Pemba, the overall prevalence of microhaematuria
and S. haematobium infection was 19.4 % (95 % CI:
Table 2 Reasons for not receiving or taking praziquantel during community-wide treatment in Zanzibar in 2013
Unguja Pemba
n % n %
Either did not receive or did not take the drug 1060 1254
Gave at least one reason for not receiving or taking the drug 699 1156
Did not provide any reason 361 34.1 98 7.8
Reason provided:
Pregnant 163 23.3 193 16.7
Breastfeeding 36 5.2 67 5.8
Sick 27 3.9 30 2.6
Absent < 5 days 119 17.0 228 19.7
Absent > 5 days 174 24.9 226 19.6
No CDD 104 14.9 76 6.6
No praziquantel left 13 1.9 11 1.0
Busy 12 1.7 88 7.6
Afraid of adverse events 16 2.3 74 6.4
Healthy 13 1.9 70 6.1
Too many tablets 2 0.3 41 3.5
Did not trust height measurement 3 0.4 25 2.2
No information about the drugs 8 1.1 16 1.4
Did not like the drug 2 0.3 14 1.2
No food available 1 0.1 9 0.8
Kept 3 0.4 7 0.6
Drug does not work 1 0.1 6 0.5
Bad CDD 0 0.0 5 0.4
Drug does affect reproduction 0 0.0 3 0.3
Fasting 3 0.4 1 0.1
Too old 2 0.3 0 0.0
Too young 0 0.0 0 0.0
Religion 0 0.0 0 0.0
Drug provided for free 0 0.0 0 0.0
CDD Community Drug Distributor
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17.2–21.5 %) and 4.0 % (95 % CI: 2.5–5.4 %), respectively. An
increase of age significantly lowered the risk of being infected
with S. haematobium (OR: 0.95, 95 % CI: 0.93–0.97 %).
In Unguja, 10.8 % (95 % CI: 9.3–12.4 %) of the adult
population was microhaematuria-positive and 2.9 % (95 %
CI: 1.7–4.0 %) excreted S. haematobium eggs. Men had
higher odds (OR: 1.9; 95 % CI: 1.1–3.5 %) and older people
lower odds (OR: 0.92; 95 % CI: 0.88–0.96 %) of being
infected with S. haematobium.
Discussion
Achieving and maintaining high MDA coverage is key
for the success of helminthiases control and elimination
programmes. We found that the SBT coverage on Pemba
and Unguja islands was 85.2 % and 86.9 %, respectively,
and hence in line with MoH reports from Pemba
(84.3 %) and higher than reports from Unguja (63.9 %).
However, in Unguja, around one third of the visited
schools had not been covered by SBT at all and was
Fig. 3 Coverage rate achieved with school-based (SBT) and community-wide treatment (CWT) in Zanzibar in November 2013. Key to colours:
White: not treated or no/invalid data; Red: coverage of 1–49 %; Orange: coverage of 50–74 %; Green: coverage of 75–100 %. a Pemba coverage
of SBT according to the Zanzibar Ministry of Health (MoH); no data were available for the schools of two shehias in Pemba. b Pemba coverage of
SBT according to our post-mass drug administration survey. c Pemba coverage of CWT according to the Zanzibar MoH. d Pemba coverage of
CWT according to our post-mass drug administration survey. e Unguja coverage of SBT according to the Zanzibar MoH; no data were available
for the schools of 19 shehias in Unguja. f Unguja coverage of SBT according to our post-mass drug administration survey (schools of 15 shehias
indicated no treatment in children attending standards 3 and 4). g Unguja coverage of CWT according to the Zanzibar MoH (no data were available
for 2 shehias and invalid data were available for another 2 shehias in Unguja). h Unguja coverage of CWT according to our post-mass
drug administration survey. Shehias in Pemba (maps a–d): 1. Makangale; 2. Msuka; 3. Konde; 4. Kinowe; 5. Tumbe; 6. Mgogoni; 7. Shumba
Viamboni; 8. Sizini; 9. Kizimbani; 10. Kinyasini; 11. Finya; 12. Selemu; 13. Jadida; 14. Pandani; 15. Mtambile Kusini; 16. Piki; 17. Mchangamdogo (no MoH
school data); 18. Kisiwani; 19. Kangagani; 20. Ziwani; 21. Ole; 22. Uwandani; 23. Mbuzini; 24. Kwale; 25. Wesha; 26. Tibrinzi; 27. Ng’ambwa; 28. Vitongoji;
29. Wawi; 30. Chanjaani; 31. Shungi (no MoH school data); 32. Matale; 33. Pujini; 34. Wambaa; 35. Ngwachani; 36. Ukutini; 37. Chambani; 38. Makombeni;
39. Ng’ombeni; 40. Mtambile; 41. Michenzani; 42. Mkanyageni; 43. Kangani; 44. Kengeja; 45. Kiwani. Shehias in Unguja (maps e–h): 1. Mkwajuni; 2. Donge
Mchangani; 3. Pale; 4. Gamba; 5. Mafufuni; 6. Makoba; 7. Donge Mtambile; 8. Chaani Masingi; 9. Kandwi; 10. Donge Mnyimbi; 11. Mahonda; 12. Bandamaji;
13. Mgambo; 14. Kinyasini; 15. Upenja; 16. Fujoni; 17. Kitope; 18. Kilombero; 19. Kama; 20. Mfenesini; 21. Mwakaje, 22. Chuini; 23. Mbuzini; 24. Miwani; 25.
Kiboje Mkwajuni; 26. Uzini; 27. Mwanyanya (for e and f shehia highlighted since school coordinates not available); 28. Dole; 29. Mtoni; 30. Kianga; 31. Mwera
shehia / Regeza Mwendo school; 32. Ubago; 33. Jumbi; 34. Fuoni Kibondeni; 35. Jendele; 36. Cheju; Inset map: 37. Mtopepo; 38. Welezo; 39. Mchangani; 40.
Kilimahewa Juu; 41. Muungano; 42. Sebleni; 43. Nyerere; 44. Mwanakwerekwe; 45. Melinne; 46. Koani; 46.a Machui school (Koani shehia); 46.b Mwera school
(Koani shehia); 47. Chaani Mcheza Shauri (only CWT maps g and h); 48. Bububu school (only SBT maps e and f)
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Table 3 Reported and observed coverage of school-based and community-wide treatment in Zanzibar in 2013. Treatment coverage according to community drug distributor
reports to the Ministry of Health (MoH) and coverage and compliance according to the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) post-mass
drug administration (MDA) survey carried out as part of a parasitological survey from March to May 2014, 3–5 months after the school-based and community-wide treatment
with praziquantel in November 2013 on Unguja and Pemba islands, United Republic of Tanzania
MoH data SCORE post-MDA survey
Number treated/
number surveyed
Population Treated
population
% Treated Surveyed
population
Received
treatment
Received and
swallowed
tablets
% Received
treatment
95 % CI Design
effect
% Received
and swallowed
tablets
95 % CI Design
effect
Unguja
Schools: registered population 27c/48 26,612 17,005 63.9 2754 2394 86.9 81.0–92.9 20.10
Shehias: total
population
43b/47 181,434 122,860 67.7 2123 1378 1147 64.9 60.7–69.1 4.0 54.0 50.3–57.7 2.9
Shehias: eligible populationa 43b/47 152,362 122,860 80.6 1907 1358 1147 71.2 66.6–75.8 4.9 60.1 55.9–64.4 3.5
Pemba
Schools: registered
population
43d/45 28,235 23,807 84.3 4803 4092 85.2 81.8–88.6 10.7
Shehias: total
population
45/45 224,518 132,475 59.0 2231 1196 977 53.6 50.4–56.8 2.2 43.8 40.5–47.1 2.4
Shehias: eligible
populationa
45/45 161,597 132,475 82.0 1940 1166 976 60.1 56.5–63.7 2.6 50.3 46.6–54.0 2.7
95 % CI: 95 % confidence intervals
aPeople who were sick, pregnant or breastfeeding were excluded from analysis
bFour shehias were excluded from analysis due to problems with data obtained from the MoH (Upenja had duplicate, Miwani had invalid, and Gamba and Makoba had no MoH data)
c21 schools were excluded from analysis. Reason: no MoH data were available for 19 schools in Unguja (among them, 13 schools also did not report any treatment in the post-MDA survey) and 2 additional schools,
which reported no treatment in the post-MDA survey
dTwo schools were excluded from analysis. Reason: no MoH data were available for the schools of two shehias in Pemba (Shungi and Mchanga Mdogo)
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excluded from this analysis. The CWT compliance ob-
served in our post-MDA survey was significantly lower
than the coverage reported by the MoH. While accord-
ing to the CDD reports more than 80 % of the eligible
population had received treatment in the CWT, we
found that only 71.2 % and 60.1 % of the eligible adult
population in Unguja and Pemba, respectively, had re-
ceived praziquantel and that only 60.1 % and 50.3 %, re-
spectively, of the eligible adult population complied with
the praziquantel intake. In our study population, the
main reasons for not having received or taken the drugs
were absence during CWT, no drug distributor coming,
being busy, fear of adverse events, pregnancy, breast-
feeding or feeling healthy.
Our findings have important implications for the
schistosomiasis elimination project in Zanzibar. While
more than 75 % of pupils were treated during the SBT
coverage in the targeted schools, the MoH will need to
make an effort to reach out to all schools in Zanzibar,
including all public and private schools, nurseries and
madrassas (Koran schools). One reason for not reaching
all schools during the November 2013 treatment in
Unguja was that the SBT was conducted during the
examination period and thus access to schools was
restricted, children could not be treated during examin-
ation or were absent when not participating in examina-
tions. Timing of the SBT is hence crucial for achieving
high national coverage. The high coverage (>75 %)
achieved in most of the targeted schools is likely due to
the close supervision of teachers by the members of the
NTD Control Programme team and the provision of
porridge to children before treatment, which might have
motivated them to come to school and mitigated the
fear and occurrence of adverse events as suggested
elsewhere [31, 32, 37].
The low coverage and compliance achieved during
the CWT in Zanzibar as revealed in our post-MDA
survey including adults shows that the approach to
send CDDs to the houses was not very successful and
that the CDD’s records over-reported treatment. A
limitation of our study is that we did not assess the
CDD’s motivation to distribute the drugs, the training
they received or oversight and supervision for report-
ing. Further qualitative exploration is needed to better
understand these gaps.
A lack of respect for the CDD, the smell and size of
the tablets and the use of height, instead of weight, to
determine the dosage, and the fear of side effects, infer-
tility or even death have discouraged people from taking
the drugs in previous studies conducted elsewhere in
Africa [38–40]. In our survey, these issues were raised
by few people, who had not taken the drugs. However,
many people did not state a reason at all, and if a reason
was given, it was mostly that people were absent from
home on the days of CWT, were pregnant or breastfeed-
ing. One might correctly argue that mobilisation and
sensitisation of the community needs to be improved in
future CWT in Zanzibar to achieve a better drug cover-
age. Moreover, pregnant and lactating women should be
included into the treatment [13]. The implementation of
robust qualitative inquiries could uncover more detailed
reasons, which discourage community members from
swallowing the tablets and also highlight how best to en-
courage community involvement in CWT and SBT. Our
study showed that the knowledge of what disease was
treated with praziquantel and about the necessity of
taking tablets in the correct amount was only moderate to
low in the adult population. Hence, better theory-based,
culturally appropriate health communication about schis-
tosomiasis and the negative health impact of schistosom-
iasis is critical.
However, we also need to challenge the approach of
CWT for elimination purposes. After decades of fairly
regular MDA in Zanzibar, prevalences and infection in-
tensities of urogenital schistosomiasis have dropped to
very low levels or zero in many areas, while high preva-
lences persist or rebound in other “hot-spot” areas [6, 7,
12]. The regular administration of drugs might have
caused treatment fatigue in people and, particularly in
areas of very low endemicity the inducement to receive
and take the antischistosomal drug is low, when consid-
ering the daily income loss when waiting for a CDD.
Moreover, the large-scale distribution of praziquantel
to a population that is only marginally infected with
S. haematobium is debatable, particularly since funds
for drug distribution are limited. Elimination efforts
might be more successful and cost-effective when
CWT is focussed to hot-spot areas and a rigorous
surveillance and response strategy is implemented in
all health facilities across the islands [41]. For surveil-
lance in Zanzibar, routine diagnosis, for example with
reagent strips, will need to be implemented in public
health care units, dispensaries, public health care cen-
tres and general hospitals and, for response, praziquan-
tel treatment be made available in these peripheral centres
and provided to suspected and confirmed cases. Since
praziquantel treatment is also considered safe in preg-
nancy [42, 43], but often not received or taken by preg-
nant or lactating women, it will also be important to
expand and improve the service of guidance, diagnosis
and treatment to mother and child health care units.
On the other hand, previous research in Pemba has
shown that the S. haematobium prevalence is underesti-
mated when diagnosed by a single urine filtration and that
considerably higher prevalences are revealed when an
ultra-sensitive diagnostic test such as the up-converting
phosphor lateral flow circulating anodic antigen (UCP-LF
CAA) assay, is used [44]. Hence, unrecognised and
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untreated children and adults might constitute important
parasite reservoirs that contribute to the spread of the dis-
ease and rapid reinfection [39, 45]. Considering that our
post-MDA survey was conducted only 3–5 months after
the last SBT and CWT and that a considerable number of
treated individuals (4.7 % of children and 3.4 % of adults)
were found to be S. haematobium-positive, the reinfection
potential in certain hot-spot communities in Zanzibar
seems to be relatively high, although incomplete cure by
praziquantel might also be a plausible explanation [7, 46–
48]. Achieving and maintaining high MDA coverage and
compliance at national and local level and additionally
treating infected individuals in health facilities are there-
fore crucial to avoid a rebound of S. haematobium
infection. Highly sensitive diagnostic tests and additional
control measures such as snail control and behaviour
change interventions will be needed to interrupt transmis-
sion completely [18, 44, 49, 50]. The possibility of emer-
ging drug resistance in Zanzibar, where praziquantel has
been distributed regularly for more than 10 years, needs
to be clarified and hopefully ruled out in future studies
assessing praziquantel efficacy.
Limitations of our study are that, while our inter-
viewers were trained and the questionnaires pretested,
reporting bias cannot be ruled out completely and re-
spondents might have provided socially desirable re-
sponses or might not have been able to recall treatment
correctly. Moreover, our interviewers were not fully in-
dependent MoH staff but part of the NTD Control
Programme team that implemented the MDA. Since,
however, our results suggest an over-reporting of CWT
coverage by the CDDs, we feel that the data collected in
our post-MDA survey are reliable. For information on
the SBT, we only included children from standards 3
and 4 in our survey, and results might not be generalis-
able for the whole schools. Finally, the schools and
shehias investigated in our survey were not selected
newly at random but comprised the settings included
and annually surveyed in the SCORE randomised oper-
ational research project, which might have introduced a
bias. A future post-MDA survey conducted by independ-
ent staff and in a sample of schools and communities
that are selected newly and completely at random might
shed light on the situation across the islands and show if
the settings targeted by the SCORE operational research
trial differ from the remaining schools and shehias in
Zanzibar.
Conclusion
To strengthen the elimination efforts in Zanzibar, SBT
will need to be extended to all public and private
schools, nurseries and madrassas. To overcome potential
treatment fatigue in the communities and to increase
coverage and compliance in adults, the implementation
of the CWT needs to be improved and mobilization and
sensitization enhanced. To reach elimination of urogeni-
tal schistosomiasis transmission in Zanzibar and else-
where, achieving and maintaining very high treatment
coverage and compliance at national and local level is
key and additional control measures such as snail con-
trol and behaviour change interventions will need to be
implemented area wide.
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